Raymond James & Associates Galapagos Nv Transaction History

Raymond James & Associates

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$68.86 - $83.34 $392,570 - $475,121	-5,701 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$76.15 - $111.94 $60,767 - $89,328	798 Added 16.28%	5,701 $439,000
Q4 2020 Feb 12, 2021	BUY	$96.85 - $148.25 $107,600 - $164,705	1,111 Added 29.3%	4,903 $485,000
Q3 2020 Nov 04, 2020	BUY	$122.47 - $213.56 $51,192 - $89,268	418 Added 12.39%	3,792 $538,000
Q2 2020 Jul 28, 2020	BUY	$185.52 - $231.25 $177,728 - $221,537	958 Added 39.65%	3,374 $666,000
Q1 2020 Apr 21, 2020	BUY	$143.0 - $274.03 $28,743 - $55,080	201 Added 9.07%	2,416 $473,000
Q4 2019 Feb 12, 2020	BUY	$146.12 - $215.82 $84,895 - $125,391	581 Added 35.56%	2,215 $458,000
Q3 2019 Nov 07, 2019	BUY	$130.44 - $187.64 $213,138 - $306,603	1,634 New	1,634 $249,000

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.85B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.